[Intestinal absorption of digoxin in systemic sclerosis (author's transl)].
Gastro-intestinal absorption of digoxin was evaluated in 18 patients with progressive systemic sclerosis. In 8 patients a single-dose crossover study was performed after oral and intravenous administration of 0.5 mg digoxin by comparing the aera under the eight-hour plasma concentration curve. The fraction of the dose absorbed was diminished in 4 patients to less than 55%. There was a significant positive correlation between the extent of digoxin absorption and xylose renal excretion. In addition, steady state digoxin plasma levels and 24-h urinary excretion of digoxin were determined during maintenance therapy in 12 patients. In 6 patients renal excretion of digoxin was clearly less than in normal subjects during chronic dosing of the same digoxin preparation. This finding corresponded well with digoxin plasma levels below the usual therapeutic range in most of the patients. The impaired absorption of digoxin failed to correlate with the extent of the skin manifestation or the time course of the disease while there was massive oesophageal dysfunction in most of these patients. The results suggest that an inadequate therapeutic response to cardiac glycosides in patients suffering from progressive systemic sclerosis is at least partially due to impaired digoxin absorption. Similar problems could occur in therapy of the disease itself due to insufficient enteral absorption of drugs used in treatment of systemic sclerosis.
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D004077:Digoxin / Q000008:administration & dosage / Q000378:metabolism*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007408:Intestinal Absorption; D007421:Intestine, Small / Q000378:metabolism; D008286:Malabsorption Syndromes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000378:metabolism*; D014994:Xylose / Q000652:urine
D004077:Digoxin; D014994:Xylose
Die intestinale Resorption von Digoxin bei Patienten mit progressiver Sklerodermie